Sweden's BioGaia Q1 sales, operating profit rise

Biogaia AB

07/05/2026 07:09

Overview

Sweden probiotics maker's Q1 net sales rose 2% yr/yr, operating profit up 4%

Adjusted EPS for Q1 was SEK 0.78, nearly flat yr/yr

Company saw strong EMEA growth and expanded direct distribution in Germany and Austria

Outlook

BioGaia says it remains focused on driving sustainable growth and expanding in key markets

Company aims to capture future opportunities to drive sales and profitability

Result Drivers

PRODUCT DEMAND - Higher sales of BioGaia Protectis Drops, Prodentis, and Gastrus Pure Action drove growth in both Pediatrics and Adult Health segments

DIRECT DISTRIBUTION EXPANSION - Transition to direct distribution in Germany and Austria contributed to strong EMEA performance, especially in France and Germany

SCIENTIFIC VALIDATION - Recent studies on L. reuteri Protectis and LongevityGuard technology supported product credibility and differentiation

Company press release: ID:nWkr2lLds0

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
SEK 372.60 mln
SEK 354 mln (2 Analysts)
Q1 Adjusted EPS
SEK 0.78
Q1 Net Income
SEK 79.40 mln
Q1 EBIT
Beat
SEK 101.20 mln
SEK 96.55 mln (2 Analysts)
Q1 EBIT Margin
27.00%


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Biogaia AB is SEK150.00, about 24.9% above its May 6 closing price of SEK120.10

The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 27 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)